The retrospective study analyzed 68 treatment sessions involving 41 patients aged 5-21 years, predominantly girls with chronic migraine without aura. Patients were administered a median dose of 0.25 mg/kg/hr of IV ketamine over a median duration of 3 days.

Chronic pain and depression diagnoses are skyrocketing. There is an urgent need for more effective treatments. Ketamine was recently established to alleviate pain and depression, but many gaps remain in the scientific literature.